Hybrigenics SA completed the previously announced buyout of its unit Helixio, which provides genomic services, by its employees and managers.

Financial terms of the transaction were not disclosed.

The buyout is part of Hybrigenics' strategic refocusing on biopharmaceutical research and development, particularly on anti-cancer drugs. Following the transaction, the Paris-based company and Helixio will operate as fully independent entities.